| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/07/2002 | WO2002009767A2 Therapeutic polyanhydride compounds for drug delivery |
| 02/07/2002 | WO2002009756A1 Nerve regeneration promoters containing semaphorin inhibitor as the active ingredient |
| 02/07/2002 | WO2002009709A1 Method for reducing or eliminating smoking |
| 02/07/2002 | WO2002009707A1 Fentanyl composition for nasal administration |
| 02/07/2002 | WO2002009706A1 Agonists of follicle stimulating hormone activity |
| 02/07/2002 | WO2002009704A2 Pharmaceutical composition for transdermal delivery of befloxatone |
| 02/07/2002 | WO2002009701A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/07/2002 | WO2002009694A1 Anticonvulsant derivatives useful for the treatment of depression |
| 02/07/2002 | WO2002009686A2 Cdc25 phosphatase inhibitors |
| 02/07/2002 | WO2002009675A1 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release |
| 02/07/2002 | WO2001081310A8 1-aroyl-piperidinyl benzamidines |
| 02/07/2002 | WO2001078755A3 A novel polypeptide - human ataxia-telangiectasia mutant protein 9 and a polynucleotide encoding the same |
| 02/07/2002 | WO2001078652A3 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/07/2002 | WO2001074811A3 Substituted 1,3-thiazole compounds, their production and use |
| 02/07/2002 | WO2001060806A3 Substituted arylpyrazines |
| 02/07/2002 | WO2001058470A3 Methods for enhancing the bioavailability of a drug |
| 02/07/2002 | WO2001053469A3 Phosphatases |
| 02/07/2002 | WO2001029255A9 Diagnostic test for cephalic pain |
| 02/07/2002 | WO2001028539A9 Agent for treating cephalic pain |
| 02/07/2002 | WO2001024781A3 Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| 02/07/2002 | WO2001000566A3 Substituted phenoxyacetic acids |
| 02/07/2002 | US20020016976 Mutant multi-substrate enzyme which accepts at least one orthogonal substrate analog, whereby catalytic activity results in combination of all or part of orthogonal substrate with other substrate of enzyme; drug screening |
| 02/07/2002 | US20020016471 Inhibitors of p38 |
| 02/07/2002 | US20020016465 Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol |
| 02/07/2002 | US20020016464 Sodium channel blockers used to treat amyotrophic lateral sclerosis; analgesics, anticonvulsants, antidepressants, local anesthetics and antiarrhythmics |
| 02/07/2002 | US20020016370 A therapeutically effective amount of exo-R-mecamylamine or salt, substantially free of exo-S-mecamylamine in combination with a carrier; useful for treating substance addiction |
| 02/07/2002 | US20020016354 Treatment of respiratory diseases, convulsions, vascular disorders, renal disorders, urinary disorders, Alzheimer's disease, dysmenorrhea, narcolepsy |
| 02/07/2002 | US20020016348 Administering 5HT1B/1D agonist and COX-2 selective inhibitor |
| 02/07/2002 | US20020016342 Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| 02/07/2002 | US20020016337 Heterocyclic analgesic compounds and methods of use thereof |
| 02/07/2002 | US20020016336 Treatment of rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration, tumor metastasis or invasion, periodontal disease and bone disease |
| 02/07/2002 | US20020016334 Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| 02/07/2002 | US20020016331 Method of treating pain using nalbuphine and opioid antagonists |
| 02/07/2002 | US20020016328 Corticotropin releasing factor antagonists |
| 02/07/2002 | US20020016322 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use |
| 02/07/2002 | US20020016320 Inhibiting beta-secretase enzyme activity and A beta peptide production. |
| 02/07/2002 | US20020016313 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 02/07/2002 | US20020016311 Nitrate esters and their use for neurological conditions |
| 02/07/2002 | US20020016284 Detecting or measuring the amount of oxidative stress or damage in a subject suspected of having Alzheimer's disease; screening, diagnosis, therapy |
| 02/07/2002 | US20020016002 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 02/07/2002 | US20020015998 Novel G protein-coupled receptors |
| 02/07/2002 | US20020015981 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 02/07/2002 | US20020015744 Dietetic supplements; cognition activators |
| 02/07/2002 | US20020015740 Administering nitrogen oxide mimetic |
| 02/07/2002 | US20020015695 Herpesviral vectors for gene delivery |
| 02/07/2002 | DE10036818A1 Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten New N-triazolylmethyl piperazine derivatives as neurokinin receptor antagonists |
| 02/07/2002 | DE10031391A1 Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie Bicyclic compounds and their use for the prophylaxis and therapy of cerebral ischemia |
| 02/07/2002 | CA2771263A1 Therapeutic polyesters and polyamides |
| 02/07/2002 | CA2425889A1 Agonists of follicle stimulating hormone activity |
| 02/07/2002 | CA2418115A1 Imidazole derivatives |
| 02/07/2002 | CA2418107A1 Method for reducing or eliminating smoking |
| 02/07/2002 | CA2417900A1 C3b/c4b complement receptor-like molecules and uses thereof |
| 02/07/2002 | CA2417650A1 Indazole derivatives as jnk inhibitors and compositions and methods related thereto |
| 02/07/2002 | CA2417638A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| 02/07/2002 | CA2417612A1 C3b/c4b complement receptor-like molecules and uses thereof |
| 02/07/2002 | CA2417568A1 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | CA2417550A1 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 02/07/2002 | CA2417444A1 Nonsteroidal inflammation inhibitors |
| 02/07/2002 | CA2417359A1 Protein phosphatases |
| 02/07/2002 | CA2417356A1 Directed differentiation of embryonic cells |
| 02/07/2002 | CA2417349A1 Novel proteins and nucleic acids encoding same |
| 02/07/2002 | CA2417304A1 Anticonvulsant derivatives useful for the treatment of depression |
| 02/07/2002 | CA2417277A1 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| 02/07/2002 | CA2417262A1 Cdc25 phosphatase inhibitors |
| 02/07/2002 | CA2417259A1 Process for preparing arylacetylaminothiazoles |
| 02/07/2002 | CA2417204A1 Imidazolyl derivatives |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2417121A1 Imidazo-pyrazine derivatives as ligands for gaba receptors |
| 02/07/2002 | CA2417059A1 3-substituted isoquinolin-1-yl derivatives |
| 02/07/2002 | CA2415851A1 Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase |
| 02/07/2002 | CA2414623A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
| 02/07/2002 | CA2385908A1 Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
| 02/06/2002 | EP1178115A2 Phosphodiesterase |
| 02/06/2002 | EP1178053A2 Polypeptides and polynucleotides coding therefor from a family of G-protein coupled receptors and their use for the diagnosis and treatment of skin diseases |
| 02/06/2002 | EP1178048A1 Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists |
| 02/06/2002 | EP1178047A1 Diazabicyclooctane derivatives and therapeutic uses thereof |
| 02/06/2002 | EP1178045A1 Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents |
| 02/06/2002 | EP1178034A1 Alkyl amino acid derivatives useful as pharmaceutical agents |
| 02/06/2002 | EP1177798A2 A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent |
| 02/06/2002 | EP1177797A1 Novel use |
| 02/06/2002 | EP1177792A2 Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| 02/06/2002 | EP1177790A1 Therapy with cannabinoids in the treatment of cerebral tumor |
| 02/06/2002 | EP1177445A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities |
| 02/06/2002 | EP1177435A1 Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype |
| 02/06/2002 | EP1177312A2 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177295A1 Ox2 receptor homologs |
| 02/06/2002 | EP1177293A1 Growth factor homolog zvegf4 |
| 02/06/2002 | EP1177291A2 Laminin 8 and methods for its use |
| 02/06/2002 | EP1177287A2 Secreted human proteins |
| 02/06/2002 | EP1177208A1 Spray drying of thrombin inhibitors |
| 02/06/2002 | EP1177206A1 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anaesthetic activity |
| 02/06/2002 | EP1177200A1 Ligands for metabotropic glutamate receptors |
| 02/06/2002 | EP1177197A2 Polyamines and their use in therapy |
| 02/06/2002 | EP1177196A1 Heteroaryl diazabicycloalkanes, their preparation and use |
| 02/06/2002 | EP1177195A1 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/06/2002 | EP1177185A1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents |
| 02/06/2002 | EP1177181A1 Substituted bicyclic compounds |
| 02/06/2002 | EP1177178A1 Heterocyclically substituted benzimidazoles, the production and application thereof |
| 02/06/2002 | EP1177177A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |